Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

DEXCOM INC Director's Dealing 2016

Mar 10, 2016

30198_dirs_2016-03-10_4dafa85f-49ab-48c2-99ab-ffead5340017.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2016-03-08

Reporting Person: SAYER KEVIN R (Director, President & CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2016-03-08 Common Stock A 90000.0 $0.0010 Acquired 426402 Direct

Footnotes

F1: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting over a 36 month period from the date of grant as follows: 1/3 shall vest 12 months from the Grant Date, and the remaining balance shall vest in four equal installments over the following 24 months. Share units represent a contingent right to receive one share of DexCom, Inc. common stock.

F2: Included in this number are 225,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 60,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018, 50,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017, and 25,000 of which were granted on March 11, 2013 and shall vest through March 11, 2016.